FOR PATIENTS for whom the potential short-term benefits of insomnia relief by benzodiazepine therapy are offset by their specific vulnerability to both acute and long-term adverse effects or dependency, the study by Garfinkel and colleagues1 using melatonin therapy for discontinuation offers a hopeful adjunct in the weaning process and a sleep-maintenance alternative to benzodiazepine therapy. Alternatives such as melatonin therapy can be also helpful in maintaining a therapeutic alliance by offering a treatment enabling focus instead of a do-or-die crisislike atmosphere that can surround the encounter between a concerned clinician and a vulnerable, anxious patient seeking or already dependent on benzodiazepines. Thus, for clinicians who treat patients who are benzodiazepine-dependent and suffer from insomnia, an informed consent process that offers melatonin therapy as an alternative to benzodiazepine dependence integrates good clinical care with effective risk management by carefully navigating between the Scylla of addiction and the Charybdis of abandonment.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Care at the Close of Life EDUCATION GUIDES
Management of Dyspnea in Patients With Far-Advanced Lung Disease
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.